US 12,753,240 B2 · Anti-tumor necrosis factor receptor (TNFR2) antibodies and uses thereof

Anti-tumor necrosis factor receptor (TNFR2) antibodies and uses thereof

AssigneeBiolojic Design Ltd.

InventorsInbar Amit, Itay Levin, Ayelet Chen, Tal Vana, Nino Oren, Dor Samet, Efrat Choen Zada, Natalia Levitin, Guy Nimrod, Yehezkel Sasson, Alik Demishtein, Timothy Wyant, Reut Barak Fuchs, Yair Fastman, Sharon Fischman, Marek Strajbl, Michael Zhenin, Olga Bluvshtein Yermolaev, Noam Grossman, Oshrat Shir Twito, Nevet Zur Biton, Liron Danielpur, May Sofia Ben Mayor, Yanay Ofran

Life of this patent

Estimating the term…

Abstract

The present disclosure describes a number of anti-TNFR2 (tumor necrosis factor receptor 2) antibodies. These antibodies are TNFR2 agonists. In certain cases, these antibodies agonize TNFR2 in an Fc independent manner. These antibodies can modulate the proliferation and/or functions of regulatory T cells and myeloid-derived suppressor cells. In certain instances, these antibodies can be used to treat diseases such as GvHD or autoimmune diseases.

Claims16

Dependent claims

An isolated anti-TNFR2 (tumor necrosis factor receptor 2) antibody comprising a set of three complementarity determining regions (CDRs) on a heavy chain (HCDR1, HCDR2, and HCDR3) and a set of three CDRs on a light chain (LCDR1, LCDR2, and LCDR3), wherein said CDRs have the amino acid sequences of

SEQ ID NO:
187, SEQ ID NO:345, and SEQ ID NO:
356 (HCDR1, HCDR2, and HCDR3, respectively), and SEQ ID NO:
371, SEQ ID NO:
377, and SEQ ID NO:
395 (LCDR1, LCDR2, and LCDR3, respectively).

3 more elements

Dependencies are inferred from the claim text.

Facts

Application

18/011,251Filed 1 Jul 2021 · us provisional application

Priority

2 Jul 2020

Published

US 2023/0167188 A11 Jun 2023

Granted

6 Oct 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification10 codes

C07K 16/2878
Against receptors, cell surface antigens or cell surface determinants: against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
A61K 35/17
Blood; Artificial blood: lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
A61P 37/02
Drugs for immunological or allergic disorders: immunomodulators
C12N 15/63
Recombinant DNA-technology: introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression